#1 Clinical Trials Search in Europe

Febuxostat Hemihydrate

This article explores the use of Febuxostat Hemihydrate in clinical trials, specifically focusing on a study comparing different urate-lowering therapies for gout treatment. The trial aims to assess the effectiveness of continuing versus stopping these therapies in patients with gout in remission, providing valuable insights into optimal treatment strategies and their cost-effectiveness.

Table of Contents

What is Febuxostat?

Febuxostat hemihydrate, commonly known as Febuxostat, is a medication used in the treatment of gout. It belongs to a class of drugs called xanthine oxidase inhibitors.[1] Febuxostat is considered a urate-lowering therapy (ULT), which means it helps reduce the levels of uric acid in the body.

How Does Febuxostat Work?

Febuxostat works by blocking an enzyme called xanthine oxidase. This enzyme is responsible for producing uric acid in the body. By inhibiting this enzyme, Febuxostat helps to lower the amount of uric acid in the blood, which is the primary cause of gout symptoms.[1]

Uses of Febuxostat

The primary use of Febuxostat is in the treatment of gout. Gout is a form of arthritis caused by the buildup of uric acid crystals in the joints, leading to pain, swelling, and inflammation. Febuxostat is typically prescribed for patients who have been diagnosed with gout and need long-term management of their uric acid levels.[1]

Dosage Information

According to the clinical trial information, the maximum daily dose of Febuxostat is 120 mg.[1] However, it’s important to note that dosage can vary depending on individual patient needs and should always be determined by a healthcare professional.

Current Clinical Trial: GO TEST FINALE Study

Febuxostat is currently being studied in a clinical trial called the GO TEST FINALE study. This trial is comparing different treatment strategies for gout patients who have achieved remission.[1]

Key points about the study:

  • It’s comparing the continuation versus cessation of urate-lowering therapies (including Febuxostat) in gout patients who have achieved remission.
  • The study aims to determine which strategy is more effective in maintaining gout remission over a 24-month period.
  • Participants in the study have been in gout remission for at least 12 months, meaning they’ve been free of gout flares and visible tophi (uric acid deposits under the skin).
  • The study is also looking at the cost-effectiveness of different treatment strategies.

Important Considerations for Patients

If you’re considering or currently taking Febuxostat, here are some important points to keep in mind:

  1. Long-term use: Febuxostat is typically used as a long-term treatment for gout. The clinical trial is studying its use over a 24-month period.[1]
  2. Monitoring: While on Febuxostat, your doctor will likely monitor your uric acid levels regularly to ensure the medication is effective.
  3. Gout flares: When starting Febuxostat, you might experience an increase in gout flares initially. This is normal and doesn’t mean the medication isn’t working. Your doctor may prescribe additional medications to manage these flares.
  4. Other medications: Febuxostat may be used alongside other gout medications like colchicine, NSAIDs, or prednisone for flare management.[1]
  5. Cardiovascular health: If you have a history of heart problems, especially recent heart attack or stroke, make sure to discuss this with your doctor before starting Febuxostat.[1]

Remember, Febuxostat is a prescription medication and should only be taken under the guidance of a healthcare professional. Always follow your doctor’s instructions regarding dosage and report any side effects or concerns you may have.

Aspect Details
Study Title GOut TrEatment STrategy (GO TEST) FINALE study
Main Objective Compare continuation vs. cessation of urate-lowering therapies in gout remission
Medications Studied Allopurinol, Benzbromarone, Febuxostat Hemihydrate
Study Duration 24 months
Primary Endpoint Proportion of patients maintaining gout remission
Key Inclusion Criteria Gout diagnosis, ULT use, achieved remission for ≥12 months, age ≥18 years
Key Exclusion Criteria Language barriers, life expectancy <2 years, contraindications for flare treatments
Febuxostat Hemihydrate Details Max daily dose: 120 mg, Route: Oral, Treatment period: up to 24 months

FAQ

  • What is the main goal of the clinical trial using Febuxostat Hemihydrate? The main goal is to compare the effectiveness of continuing versus stopping urate-lowering therapies, including Febuxostat Hemihydrate, in patients with gout who have achieved remission. The study aims to determine which strategy is better for maintaining remission and evaluate the cost-effectiveness of these approaches.
  • Who can participate in this clinical trial? Participants must be at least 18 years old, have a clinical diagnosis of gout, be using urate-lowering therapy (such as Febuxostat Hemihydrate), and have achieved gout remission for at least 12 months. They must also be able to speak, read, and write Dutch, and provide informed consent.
  • How long does the clinical trial last? The clinical trial has a follow-up period of 24 months (2 years). During this time, participants will visit the hospital 3 times and have blood tests taken 3-4 times, depending on their assigned group.
  • What are the potential risks of participating in this trial? The researchers consider the risk of participating in this study to be very low. All medications used, including Febuxostat Hemihydrate, are already registered for gout treatment. To reduce the risk of gout attacks, medication is gradually reduced in one group. Participants may experience some time burden due to hospital visits and questionnaires.
  • How will the effectiveness of the treatment strategies be measured? The effectiveness will be measured by assessing the proportion of participants who meet adapted preliminary gout remission criteria during the last six months of the 24-month follow-up period. These criteria include no tophi, no flares, low pain levels, and low disease activity, regardless of serum urate levels.

Ongoing Clinical Trials on Febuxostat Hemihydrate

  • Study on the Safety and Effectiveness of Venetoclax with Fludarabine, Amsacrine, and Cytarabine for Patients with MDS, CMML, or Secondary AML Undergoing Stem Cell Transplantation

    Recruiting

    1 1 1
    Investigated drugs:
    Germany

  • Study on Gout Treatment: Comparing Allopurinol, Benzbromarone, and Febuxostat in Patients with Gout in Remission

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Gout: A form of arthritis caused by a buildup of uric acid crystals in the joints, leading to inflammation, pain, and swelling.
  • Urate-lowering therapy (ULT): Medications used to reduce the levels of uric acid in the blood, which helps prevent gout attacks and complications.
  • Febuxostat Hemihydrate: A medication used as a urate-lowering therapy for gout treatment, which works by reducing the production of uric acid in the body.
  • Remission: A state in which the symptoms of a disease, in this case gout, are reduced or absent for a period of time.
  • Tophi: Deposits of uric acid crystals that can form under the skin or in joints of people with chronic gout.
  • Flare: A sudden worsening or recurrence of gout symptoms, typically characterized by pain, swelling, and inflammation in affected joints.
  • Serum urate: The level of uric acid in the blood, which is a key factor in gout development and management.
  • QALY: Quality-Adjusted Life Year, a measure used in health economics to assess the value of medical interventions in terms of both quantity and quality of life.
  • ACR-EULAR gout criteria: A set of diagnostic criteria for gout developed by the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR).
  • NSAID: Non-Steroidal Anti-Inflammatory Drug, a type of medication used to reduce pain, fever, and inflammation, often used in gout treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-gout-treatment-comparing-allopurinol-benzbromarone-and-febuxostat-in-patients-with-gout-in-remission/